|1.||Teplán, I: 1 article (01/2000)|
01/01/1992 - "In this study we report that in 9,10-dimetyl-1,2-bezanthracene- induced mammary carcinomas in rats, Folligen caused an almost 100% tumour remission during a 3-week daily treatment, without blocking ovarian functions. "
09/01/1992 - "Our GnRH analog Folligen, had significant antitumor activity on DMBA induced mammary carcinomas in rats without blocking ovarian functions. "
|2.||Breast Neoplasms (Breast Cancer)
01/01/2000 - "One of the most effective antitumor analog was patented under the name FOLLIGEN which inhibited the breast cancer caused by DMBA in rats without any side-effects. "
09/01/1992 - "The direct effect of Folligen and Buserelin has been compared on the human breast cancer cell line MDA-MB-231. "
01/01/1991 - "The results also suggest that folligen and buserelin might have a different mechanism of action on this human breast cancer cell line."
01/01/1991 - "The direct effect of folligen and a well-known superactive GnRH analogue, buserelin, on the MDA-MB-231 human breast cancer cell line was investigated. "
|2.||Gonadotropin-Releasing Hormone (GnRH)